Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.25 (
MEKK1
)
1,856
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The prototype mitogen-activated protein (MAP) kinase module is a three-kinase cascade consisting of the MAP kinase, extracellular signal-regulated protein kinase (ERK) 1 or ERK2, the MAP/ERK kinase (MEK) MEK1 or MEK2, and the
MEK kinase
, Raf-1 or B-Raf. This and other MAP kinase modules are thought to be critical signal transducers in major cellular events including proliferation, differentiation, and stress responses. To identify novel mammalian MAP kinase modules, polymerase chain reaction was used to isolate a new MEK family member,
MEK5
, from the rat.
MEK5
is more closely related to MEK1 and MEK2 than to the other known mammalian MEKs, MKK3 and MKK4.
MEK5
is thought to lie in an uncharacterized MAP kinase pathway, because
MEK5
does not phosphorylate the ERK/MAP kinase family members ERK1, ERK2, ERK3, JNK/SAPK, or p38/HOG1, nor will Raf-1, c-Mos, or
MEKK1
highly phosphorylate it. Alternative splicing results in a 50-kDa alpha and a 40-kDa beta isoform of
MEK5
.
MEK5
beta is ubiquitously distributed and primarily cytosolic.
MEK5
alpha is expressed most highly in liver and brain and is particulate. The 23 amino acids encoded by the 5' exon in the larger alpha isoform are similar to a sequence found in certain proteins believed to associate with the actin cytoskeleton; this alternatively spliced modular domain may lead to the differential subcellular localization of
MEK5
alpha.
...
PMID:Isolation of MEK5 and differential expression of alternatively spliced forms. 749 18
Big mitogen-activated protein (MAP) kinase (BMK1), also known as ERK5, is a member of the MAP kinase family whose cellular activity is elevated in response to growth factors, oxidative stress, and hyperosmolar conditions. Previous studies have identified
MEK5
as a cellular kinase directly regulating BMK1 activity; however, signaling molecules that directly regulate
MEK5
activity have not yet been defined. Through utilization of a yeast two-hybrid screen, we have identified
MEKK3
as a molecule that physically interacts with
MEK5
. This interaction appears to take place in mammalian cells as evidenced by the fact that cellular
MEK5
and
MEKK3
co-immunoprecipitate. In addition, we show that a dominant active form of
MEKK3
stimulates BMK1 activity through
MEK5
. Moreover, we demonstrate that
MEKK3
activity is required for growth factor mediated cellular activation of endogenous BMK1. Taken together, these results identify
MEKK3
as a kinase that regulates the activity of
MEK5
and BMK1 during growth factor-induced cellular stimulation.
...
PMID:MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. 1059 83
MEKK2
and
MEKK3
are two closely related mitogen-activated protein kinase (MAPK) kinase kinases. The kinase domains of
MEKK2
and
MEKK3
are nearly identical, although their N-terminal regulatory domains are significantly divergent. By yeast two-hybrid library screening, we have identified
MEK5
, the MAPK kinase in the big mitogen-activated protein kinase 1 (BMK1)/ERK5 pathway, as a binding partner for
MEKK2
.
MEKK2
expression stimulates BMK1/ERK5 activity, the downstream substrate for
MEK5
. Compared with
MEKK3
,
MEKK2
activated BMK1/ERK5 to a greater extent, which might correlate with a higher affinity
MEKK2
-
MEK5
interaction. A dominant negative form of
MEK5
blocked the activation of BMK1/ERK5 by
MEKK2
, whereas activation of c-Jun N-terminal kinase (JNK) was unaffected, showing that
MEK5
is a specific downstream effector of
MEKK2
in the BMK1/ERK5 pathway. Activation of BMK1/ERK5 by epidermal growth factor and H2O2 in Cos7 and HEK293 cells was completely blocked by a kinase-inactive
MEKK3
(MEKK3kin(-)), whereas MEKK2kin(-) had no effect. However, in D10 T cells, expression of MEKK2kin(-) but not MEKK3kin(-) inhibited BMK1/ERK5 activity. Two-hybrid screening also identified Lck-associated adapter/Rlk- and Itk-binding protein (Lad/RIBP), a T cell adapter protein, as a binding partner for
MEKK2
.
MEKK2
and Lad/RIBP colocalize at the T cell contact site with antigen-loaded presenting cells, demonstrating cotranslocation of
MEKK2
and Lad/RIBP during T cell activation.
MEKK3
neither binds Lad/RIBP nor is recruited to the T cell contact with antigen presenting cell.
MEKK2
and
MEKK3
are differentially associated with signaling from specific upstream receptor systems, whereas both activate the
MEK5
-BMK1/ERK5 pathway.
...
PMID:MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. 1107 40
Cross-linking of the high-affinity IgE receptor (FcepsilonRI) on mast cells with IgE and multivalent antigen triggers mitogen-activated protein (MAP) kinase activation and cytokine gene expression. We report here that MAP kinase kinase 4 (MKK4) gene disruption does not affect either MAP kinase activation or cytokine gene expression in response to cross-linking of FcepsilonRI in embryonic stem cell-derived mast cells. MKK7 is activated in response to cross-linking of FcepsilonRI, and this activation is inhibited by MAP/ERK kinase (MEK) kinase 2 (
MEKK2
) gene disruption. In addition, expression of kinase-inactive MKK7 in the murine mast cell line MC/9 inhibits c-Jun NH(2)-terminal kinase (JNK) activation in response to cross-linking of FcepsilonRI, whereas expression of kinase-inactive MKK4 does not affect JNK activation by this stimulus. However, FcepsilonRI-induced activation of the tumor necrosis factor-alpha (TNF-alpha) gene promoter is not affected by expression of kinase-inactive MKK7. We describe an alternative pathway by which
MEKK2
activates
MEK5
and big MAP kinase1/extracellular signal-regulated kinase 5 in addition to MKK7 and JNK, and interruption of this pathway inhibits TNF-alpha promoter activation. These findings suggest that JNK activation by antigen cross-linking is dependent on the
MEKK2
-MKK7 pathway, and cytokine production in mast cells is regulated in part by the signaling complex
MEKK2
-
MEK5
-ERK5.
...
PMID:Role of MEKK2-MEK5 in the regulation of TNF-alpha gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells. 1127 63
MAPK/ERK kinase kinase 2 (MEKK2) is a member of the
mitogen-activated protein kinase kinase kinase
(
MAP3K
) family of protein kinases. MAP3Ks are components of a three-tiered protein kinase pathway in which a
MAP3K
phosphorylates and activates a mitogen-activated protein kinase kinase (MAP2K), which in turn activates a mitogen-activated protein kinase (MAPK). We have previously identified residues within protein kinase subdomain X in the
MAP3K
,
MEKK1
, that are critical for its interaction with the MAP2K, MKK4, and
MEKK1
-induced MKK4 activation. We report here that kinase subdomain X also plays a critical role in MEKK2 activity. Select point mutations in subdomain X impair MEKK2 phosphorylation of the MAP2Ks, MKK7 and
MEK5
, abolish MEKK2-induced activation of the MAPKs, JNK1 and ERK5, and diminish MEKK2-dependent activation of an AP-1 reporter gene. Interestingly, the spectrum of mutations in subdomain X of MEKK2 that affects its activity is overlapping with but not identical to those that have effects on
MEKK1
. Thus, mutations in subdomain X differentially affect MEKK2 and
MEKK1
.
...
PMID:Mutations in protein kinase subdomain X differentially affect MEKK2 and MEKK1 activity. 1265 51
The Phox and Bem1p (PB1) domain constitutes a recently recognized protein-protein interaction domain found in the atypical protein kinase C (aPKC) isoenzymes, lambda/iota- and zeta PKC; members of mitogen-activated protein kinase (MAPK) modules like
MEK5
,
MEKK2
, and
MEKK3
; and in several scaffold proteins involved in cellular signaling. Among the last group, p62 and Par6 (partitioning-defective 6) are involved in coupling the aPKCs to signaling pathways involved in cell survival, growth control, and cell polarity. By mutation analyses and molecular modeling, we have identified critical residues at the interaction surfaces of the PB1 domains of aPKCs and p62. A basic charge cluster interacts with an acidic loop and helix both in p62 oligomerization and in the aPKC-p62 interaction. Subsequently, we determined the abilities of mammalian PB1 domain proteins to form heteromeric and homomeric complexes mediated by this domain. We report several novel interactions within this family. An interaction between the cell polarity scaffold protein Par6 and
MEK5
was found. Furthermore, p62 interacts both with
MEK5
and NBR1 in addition to the aPKCs. Evidence for involvement of p62 in
MEK5
-ERK5 signaling is presented.
...
PMID:Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. 1281 44
MEKK2
and
MEKK3
are MAPK kinase kinases that activate the ERK5 pathway by phosphorylating and activating the MAPK kinase,
MEK5
. Activated
MEK5
then phosphorylates and activates ERK5. PB1 domains were first defined in the p67phox and Bem1p proteins and have been shown to mediate protein-protein heterodimerization. A PB1 domain is encoded within the N-terminal portion of
MEKK2
,
MEKK3
, and
MEK5
. Herein, we analyze the functional role of
MEKK2
,
MEKK3
, and
MEK5
PB1 domains in the ERK5 activation pathway. The PB1 domains of
MEKK2
and
MEKK3
bind the PB1 domain of
MEK5
but do not significantly homo- or heterodimerize with one another in vitro. Furthermore, co-immunoprecipitation of
MEKK2
and
MEK5
from cell lysates shows that they form a complex in vivo. Deletion or mutation of the
MEKK2
PB1 domain abolishes
MEKK2
-
MEK5
complexes, demonstrating that the PB1 domain interaction is required for
MEKK2
-
MEK5
interactions. Expression in cells of the
MEKK2
or
MEKK3
PB1 domain inhibits ERK5 activation, whereas expression of a mutant
MEKK2
unable to bind the
MEK5
PB1 domain or expression of the p67phox PB1 domain has no effect on ERK5 activation. These findings demonstrate that the PB1 domain mediates the association of
MEKK2
and
MEKK3
with
MEK5
and that the respective PB1 domains of these kinases are critical for regulation of the ERK5 pathway. The free PB1 domain of
MEKK2
or
MEKK3
functions effectively to inhibit the ERK5 pathway but not the p38 or JNK pathways, demonstrating the specific and unique requirement of the
MEKK2
and
MEKK3
PB1 domain in regulating ERK5 activation.
...
PMID:PB1 domains of MEKK2 and MEKK3 interact with the MEK5 PB1 domain for activation of the ERK5 pathway. 1291 94
Mitogen-activated protein kinase (MAPK) cascades play essential roles in the transduction of extracellular signals to cytoplasmic and nuclear effectors. The MAPK kinase kinase
MEKK2
is essential for activation of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase 5 (ERK5). These pathways are important for expression of specific cytokine genes in mast cells following cross-linking of the high-affinity IgE receptor (FcepsilonRI). A consequence of ERK5 activation is activation of the transcriptional factor myocyte enhancing factor-2C (MEF2C), leading to increased c-Jun expression. We have investigated the role of MEF2C activation in mast cells and demonstrated that it requires sequential activation of the signaling cascade of
MEKK2
-
MEK5
-ERK5. Following phosphorylation of MEF2C, activated MEF2C regulates transcription of c-Jun but not TNF-alpha. Inhibition of ERK5,
MEK5
activation or activation of
MEKK2
-deficient mast cells was associated with inhibition of MEF2C phosphorylation and a decrease in c-Jun expression. Thus, these data define an activation module,
MEKK2
-
MEK5
-ERK5-MEF2C in the transcriptional activation of c-Jun in mast cells following FcepsilonRI cross-linking. These results demonstrate the novel and important,
MEKK2
-dependent role of MEF2C in induction of c-Jun expression in mast cells activated through FcepsilonRI, a pathway distinct from that involving
MEKK2
-
MEK5
-ERK5 in the regulation of mast cell cytokine production.
...
PMID:MEF2C regulates c-Jun but not TNF-alpha gene expression in stimulated mast cells. 1451 74
WNK1 belongs to a unique protein kinase family that lacks the catalytic lysine in its normal position. Mutations in human WNK1 and WNK4 have been implicated in causing a familial form of hypertension. Here we report that overexpression of WNK1 led to increased activity of cotransfected ERK5 in HEK293 cells. ERK5 activation was blocked by the
MEK5
inhibitor U0126 and expression of a dominant negative
MEK5
mutant. Expression of dominant negative mutants of
MEKK2
and
MEKK3
also blocked activation of ERK5 by WNK1. Moreover, both
MEKK2
and
MEKK3
coimmunoprecipitated with endogenous WNK1 from cell lysates. WNK1 phosphorylated both
MEKK2
and -3 in vitro, and
MEKK3
was activated by WNK1 in 293 cells. Finally, ERK5 activation by epidermal growth factor was attenuated by suppression of WNK1 expression using small interfering RNA. Taken together, these results place WNK1 in the ERK5 MAP kinase pathway upstream of
MEKK2
/3.
...
PMID:WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. 1468 Dec 16
The ERK5 signaling cascade acts through sequential activation of
MEKK2
/3,
MEK5
and ERK5 and transmits signals to a variety of stress and mitogenic related targets. In this study we examined the subcellular localization of the components of the ERK5 cascade and found that in resting, as well as in EGF-stimulated HeLa and Rat-1 cells, endogenous ERK5 is localized mainly in the nucleus. This location is different from the previously described location of exogenous ERK5, in the cytosol of resting cells, which is confirmed in this study. The reason for the different localization could be a saturation of anchoring moieties by the endogenous ERK5. Indeed, in situ detergent extraction analysis using Nonidet P-40, revealed that ERK5 is bound to detergent resistant moieties in the nucleus, while the exogenous protein fails to interact with those anchors. The upstream activator
MEK5
is also localized in the nucleus both before and after EGF stimulation and is resistant to NP-40 extraction in resting cells. ERK5 remains bound to these nuclear moieties even after stimulation, while
MEK5
is detached from the anchors but remains localized in the nucleus. Unlike ERK5 and
MEK5
, their upstream activator
MEKK2
is localized mainly in the cytosol of resting cells, and translocates into the nucleus upon EGF stimulation, allowing transmission of signals to the nuclear
MEK5
. The nuclear localization of
MEK5
and ERK5 is different from that of ERK1/2 and MEK1/2 in resting cells, indicating that each MAPK cascade uses distinct mechanisms to transmit extracellular signals to their nuclear targets.
...
PMID:MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation. 1507 38
1
2
3
4
Next >>